Note 12 - Royalty and other income

The Company had a license agreement with Qiagen that began in 2005, whereby the Company earned quarterly running royalties on the net sales of Qiagen products subject to a license until the underlying patent expired on April 24, 2018. During the years ended July 31, 2018, 2017 and 2016, the Company recorded royalty income under the agreement of approximately $712, $1,205 and $1,521 respectively, which is included in the Life Sciences products segment.